Supernus v. Macleods: Viloxazine ER Patent Suit Consolidated in 7 Days
Supernus Pharmaceuticals filed a six-patent infringement action against Macleods Pharmaceuticals in the District of New Jersey over viloxazine 100 mg extended-release capsules. The case was consolidated into related proceedings just seven days after filing, suggesting an existing parallel ANDA litigation track.
Six-Patent ANDA Salvo Over Viloxazine ER Capsules Consolidated Immediately
On 16 December 2025, Supernus Pharmaceuticals, Inc. filed suit in the U.S. District Court for the District of New Jersey against Macleods Pharmaceuticals, asserting infringement of six U.S. patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — all relating to viloxazine extended-release oral capsule formulations. The accused product is viloxazine 100 mg extended-release oral capsules, consistent with a generic ANDA challenge to Supernus’s branded Qelbree product.
The case was terminated by consolidation on 23 December 2025 — just seven days after filing. Consolidation in this context typically means the new complaint was merged into an earlier-filed related action, a common procedural step in ANDA litigation where multiple Paragraph IV certification notices trigger successive suits that courts combine for efficiency. No merits ruling, claim construction, or damages determination was issued in this docket.
A seven-day lifespan before consolidation is consistent with routine ANDA case management in the District of New Jersey rather than any substantive development. The public record in this docket is limited to the appearance notice filed by Saul Ewing LLP on behalf of Supernus; no defendant counsel of record is identified here, which further suggests the substantive dispute is proceeding under a consolidated case number. The underlying merits and any settlement remain governed by that lead docket.
Filing to Case Consolidated in 7 days
7 days from filing to consolidation — among the fastest terminations on the ANDA litigation docket
Case consolidated: what the procedural merger means for both parties
Consolidation routes the dispute to a lead docket
When a district court consolidates patent cases, the newer docket is administratively merged into an earlier-filed related action under Federal Rule of Civil Procedure 42(a). No merits ruling is issued on the consolidated docket. All substantive proceedings — claim construction, discovery, trial — continue under the lead case number. This is routine in multi-wave ANDA litigation where the same branded drug faces sequential generic challengers.
FRCP 42(a) consolidationSupernus preserves all six patent claims in the lead action
For Supernus, consolidation is procedurally neutral: all six asserted patents remain live in the consolidated proceeding. The 30-month stay triggered by the ANDA Paragraph IV filing continues to run, preserving Supernus’s market exclusivity for viloxazine ER (Qelbree) while litigation proceeds. No concession or adverse finding has been made in this docket.
30-month stay intactMacleods faces consolidated multi-patent defence in one forum
For Macleods, consolidation means defending against all six Supernus patents in a single unified proceeding alongside any other generic challengers already named in the lead case. This can increase coordination complexity but also allows shared discovery. The absence of Macleods counsel of record in this docket suggests it was absorbed into an existing action where it may already have representation.
Single consolidated forumANDA market entry timeline governed by lead-case outcome
Macleods’s ability to launch a viloxazine ER generic is contingent on the outcome of the consolidated proceeding. If the lead case results in a finding of non-infringement or invalidity, generic entry could follow promptly. A Supernus win extends exclusivity through patent expiry across the six asserted patents. Stakeholders should monitor the lead consolidated docket — not this case number — for substantive developments.
Generic entry contingent on lead caseFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | CNS-focused branded pharma company — holder of US12121523B2 and five related viloxazine ER patentsSearch in Eureka ↗ |
| Defendant | Macleods Pharmaceuticals | Individual | India-headquartered generic pharmaceutical manufacturer and ANDA filerSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The docket’s only substantive filing is a notice of appearance by Saul Ewing LLP for Supernus. No judicial ruling, consent order, or merits decision appears in this record. The basis of termination — ‘Case Consolidated’ — indicates an administrative merger rather than a litigated outcome. The enforceability of all six asserted patents remains to be determined in the lead consolidated proceeding.
US12121523B2 — Viloxazine Extended-Release Oral Capsule Formulations
The six asserted patents cover viloxazine extended-release oral capsule technology from multiple angles: formulation composition, manufacturing process, and method-of-use claims. Application dates span from US13/761757 (filed 2013) through US17/896774 (filed 2022), indicating a portfolio built over nearly a decade of product development and lifecycle management. Viloxazine is a norepinephrine reuptake inhibitor approved as Qelbree for ADHD treatment, and the ER capsule format is the core commercial embodiment protected by this patent family.
The breadth of the Supernus portfolio — six patents across composition, formulation, and method claims — creates a multi-layered barrier to generic entry that mirrors strategies employed by other CNS branded pharma companies. Generic challengers must independently invalidate or design around each asserted patent, substantially raising the litigation and development cost of market entry. Companies operating in the ADHD therapeutics or controlled-release oral dosage form space should assess their product and process designs against this portfolio, particularly the later-filed continuation patents which may carry broader or updated claim scope.
Should you run an FTO against the Supernus viloxazine ER patent portfolio?
Any company developing an extended-release formulation of viloxazine, or a structurally similar norepinephrine reuptake inhibitor in an ER oral capsule format, should conduct a formal freedom-to-operate analysis against all six Supernus patents before IND filing or ANDA submission. The portfolio’s application date spread means claim scope may vary significantly across patents, and later continuations could capture process or formulation improvements that earlier filings did not.
PatSnap Eureka’s FTO Search Agent can map each of the six Supernus patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — against your product specification, flag independent claims most likely to read on an ER viloxazine formulation, and surface prior art relevant to invalidity analysis. Automated claim-charting across the full family saves weeks of manual review for ANDA litigation teams.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Suits Over CNS Extended-Release Formulations in D.N.J.
Cases below involve Hatch-Waxman ANDA challenges to CNS extended-release formulation patents litigated in the District of New Jersey, the primary forum for this dispute.
What this case signals for the CNS ANDA and viloxazine IP landscape
Supernus’s rapid, multi-patent filing posture against Macleods is consistent with an aggressive Hatch-Waxman enforcement strategy around Qelbree.
Six-patent assertions signal a broad formulation moat around Qelbree
Supernus asserted six patents spanning multiple application generations, suggesting layered protection across the viloxazine ER formulation, composition, and method-of-use claims. Any generic challenger must design around or invalidate multiple patent families, raising the cost and complexity of successful ANDA entry.
New Jersey ANDA consolidation practice compresses docket noise
The District of New Jersey routinely consolidates sequential ANDA suits against the same drug into a single lead action. IP teams tracking Supernus enforcement should monitor the lead consolidated docket rather than individual case numbers to capture all substantive rulings on the viloxazine ER patent portfolio.
Supernus v Macleods — key questions answered
Supernus Pharmaceuticals filed a six-patent infringement suit against Macleods Pharmaceuticals in the District of New Jersey on 16 December 2025. The case was consolidated into a related proceeding on 23 December 2025 — seven days later — and no merits ruling was issued in this docket.
Supernus asserted six U.S. patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. All relate to viloxazine extended-release oral capsule formulations, the technology underlying Supernus’s branded Qelbree product.
Case consolidation under FRCP 42(a) means the new docket was administratively merged into an earlier-filed related action. No merits ruling is issued on the consolidated case. All substantive proceedings — discovery, claim construction, trial — continue under the lead case number. This is common in ANDA litigation where multiple generic filers challenge the same branded drug.
Consolidation is a procedural administrative step and does not itself affect the 30-month stay triggered by Macleods’s Paragraph IV ANDA filing. The stay continues to run in the consolidated proceeding. Supernus’s market exclusivity for viloxazine ER remains intact pending resolution of the lead consolidated action.
The accused product is viloxazine extended-release oral capsules containing 100 mg of viloxazine — consistent with a generic ANDA challenge to Supernus’s Qelbree (viloxazine ER) capsules, which are approved for the treatment of ADHD in patients 6 years and older.
PatSnap Eureka searches patents and litigation data to answer instantly.